SCHEMBL9142016

SCHEMBL9142016

CN1CCCSc2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.49
INMT O95050 1/20 0.44
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PABPC1 P11940 2/20 0.41
TSHR P16473 1/20 0.41
MAOA P21397 1/20 0.41
AVPR2 P30518 1/20 0.40
AVPR1A P37288 1/20 0.40
KDM4E B2RXH2 2/20 0.40
DRD4 P21917 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KDM1A O60341 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9628981 0.94 NOTUM (0.47) NOTUMINMTHDAC1HDAC6PABPC1
SCHEMBL3969979 0.88 NOTUM (0.56) NOTUMINMTMAOAKDM4EALDH1A1
SCHEMBL5637075 0.77 NOTUM (0.45) NOTUMHDAC1HDAC6AVPR2AVPR1A
SCHEMBL8853801 0.77 HDAC1 (0.51) NOTUMINMTHDAC1HDAC6DRD4
SCHEMBL17946171 0.77 ALDH1A1 (0.46) INMTKDM4EALDH1A1ALOX15CASP1
Hydrochloric Acid SCHEMBL5638604 0.76 NOTUM (0.44) NOTUMHDAC1HDAC6AVPR2AVPR1A
SCHEMBL627227 0.75 MAOA (0.46) NOTUMTSHRMAOAKDM4EDRD4
SCHEMBL5636013 0.74 NOTUM (0.46) NOTUMHDAC1HDAC6AVPR2AVPR1A
SCHEMBL10505042 0.74 MAPT (0.54) NOTUMHDAC1HDAC6TSHRKDM4E
SCHEMBL10352868 0.74 NOTUM (0.82) NOTUMHDAC1HDAC6AVPR2AVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270862-A1 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-10-25 US disclosed
EP-0350846-B1 Condensed heterocyclic compounds and their use in therapy HOFFMANN LA ROCHE (CH) 1995-10-11 EP disclosed
US-5420273-A Skin disorders and antitumor agents HOFFMAN-LA ROCHE INC. (US) 1995-05-30 US disclosed
US-5300522-A Treating inflammatory, allergic, rheumatic, immunological disorders HOFFMANN-LA ROCHE INC. (US) 1994-04-05 US disclosed
US-5164387-A Antitumor agents, skin disorders, antiinflammatory agents HOFFMANN-LAROCHE INC. (US) 1992-11-17 US disclosed
US-5037825-A Useful In The Treatment Of Neoplasms, Dermatoses And Aging Of The Skin HOFFMANN-LA ROCHE INC. (US) 1991-08-06 US disclosed
EP-0350846-A2 Condensed heterocyclic compounds and their use in therapy F. HOFFMANN-LA ROCHE AG (CH) 1990-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270862-A1 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES ROCK1, ROCK2, GABRR1 NOTUM 3893/4885INMT 1915/4885HDAC1 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.